Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells

British Journal of Cancer

Volumn 101, Issue 7, 2009, Pages 1130-1136

  Dingli, D ^a   Chalub, F A C C ^b   Santos, F C ^c   Van Segbroeck, S ^d   Pacheco, J M ^e  

^a MAYO CLINIC   (United States)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e UNIVERSITY OF LISBON   (Portugal)

Author keywords

Cancer dynamics; Cancer ecology; Evolutionary game theory of cancer; Multiple myeloma; Replicator cell dynamics; Somatic evolution of cancer

Indexed keywords

ARTICLE; BONE DISEASE; CANCER GROWTH; CANCER INVASION; CELL POPULATION; CELL TYPE; CONTROLLED STUDY; GENOTYPE; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOCLAST; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL;

GAME THEORY; HUMANS; MULTIPLE MYELOMA; PHENOTYPE; SELECTION, GENETIC;

EID: 70349670787     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605288     Document Type: Article

References (40)

1. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104: 2484-2491
2. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R (2003) Single vs double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349: 2495-2502
3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335: 91-97
4. Axelrod R, Axelrod DE, Pienta KJ (2006) Evolution of cooperation among tumor cells. Proc Natl Acad Sci USA 103: 13474-13479
5. Bataille R, Harousseau JL (1997) Multiple myeloma. N Engl J Med 336: 1657-1664
6. Berenson JR (2001) Bone disease in myeloma. Curr Treat Options Oncol 2: 271-283
7. Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23: 6333-6338
8. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96: 671-675
9. Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD (2001) Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 108: 1833-1841
10. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540
11. Dinarello CA (2009a) Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 27: 519-550
12. Dinarello CA (2009b) Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. Mayo Clin Proc 84: 105-107
13. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, Kumar SK, Lacy MQ, Gastineau DA, Gertz MA (2007a) In vivo and in silico studies on single vs multiple transplants for multiple myeloma. Cancer Sci 98: 734-739
14. Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, Kumar SK, Lacy MQ, Gastineau DA, Gertz MA (2007b) Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Sci 98: 1035-1040
15. Dingli D, Pacheco JM, Traulsen A (2008) Coexistance of multiple mutant clones in blood. Phys Rev E Stat Nonlin Soft Matter Phys 77: 021915
16. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36: 842-854
17. Epstein J, Yaccoby S (2003) Consequences of interactions between the bone marrow stroma and myeloma. Hematol J 4: 310-314
18. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23: 3412-3420
19. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
20. Harper KD, Weber TJ (1998) Secondary osteoporosis. Diagnostic considerations. Endocrinol Metab Clin North Am 27: 325-348
21. Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T (2004) Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 125: 38-41
22. Hofbauer J, Sigmund K (1998) Evolutionary Games and Population Dynamics First edn. Cambridge University Press: Cambridge, UK
23. Jelinek DF (1999) Mechanisms of myeloma cell growth control. Hematol Oncol Clin North Am 13: 1145-1157
24. Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev 2: 175-187
25. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351: 1860-1873
26. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA (2009) Induction of a ch. Mayo Clin Proc 84: 114-122
27. Maynard-Smith J (1982) Evolution and the Theory of Games First edn. Cambridge University Press: Cambridge
28. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy Jr JD (2008a) Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 42: 669-680
29. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy Jr JD (2008b) Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112: 196-207
30. Qiang YW, Shaughnessy Jr JD, Yaccoby S (2008c) Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112: 374-382
31. Roodman GD (2002) Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 17: 1921-1925
32. Roodman GD (2004) Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32: 290-292
33. Roux S, Mariette X (2004) The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK ligand expression. Leuk Lymphoma 45: 1111-1118
34. Terpos E, Politou M, Rahemtulla A (2003) New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 123: 758-769
35. Terpos E, Sezer O, Croucher P, Dimopoulos MA (2007) Myeloma bone disease and proteasome inhibition therapies. Blood 110: 1098-1104
36. Tomlinson IP (1997) Game-theory models of interactions between tumour cells. Eur J Cancer 33: 1495-1500
37. Tomlinson IP, Bodmer WF (1997) Modelling the consequences of interactions between tumour cells. Br J Cancer 75: 157-160
38. Traulsen A, Pacheco JM, Dingli D (2007) On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria. Stem Cells 25: 3081-3084
39. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799
40. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy Jr JD (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109: 2106-2111